Antisense modulation of B7 protein expression
US7115580B1 · kind B1 · utility
2Cited by
4References
40Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2000 |
| Grant date | Oct 3, 2006 |
| Priority date | — |
| Expiry date | May 25, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/582
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for the diagnosis, prevention and treatment of immune states and disorders amenable to treatment through modulation of T cell activation are provided. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding B7 proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.